HC Wainwright Reduces Earnings Estimates for Pharming Group

Pharming Group (NASDAQ:PHAR) – Analysts at HC Wainwright reduced their FY2027 EPS estimates for Pharming Group in a research report issued to clients and investors on Thursday, October 24th. HC Wainwright analyst J. Pantginis now anticipates that the company will post earnings per share of $2.20 for the year, down from their prior forecast of $2.42. HC Wainwright has a “Buy” rating and a $37.00 price objective on the stock. The consensus estimate for Pharming Group’s current full-year earnings is ($0.15) per share.

Pharming Group (NASDAQ:PHAR) last announced its earnings results on Thursday, August 1st. The company reported ($0.01) EPS for the quarter. Pharming Group had a negative net margin of 4.65% and a negative return on equity of 5.69%. The business had revenue of $74.09 million for the quarter, compared to the consensus estimate of $71.95 million. During the same quarter in the prior year, the company earned $0.02 EPS.

Pharming Group Price Performance

Shares of NASDAQ PHAR opened at $8.70 on Monday. The company has a 50 day simple moving average of $8.05 and a two-hundred day simple moving average of $8.53. The company has a market capitalization of $585.89 million, a price-to-earnings ratio of -54.38 and a beta of 0.15. Pharming Group has a fifty-two week low of $6.65 and a fifty-two week high of $13.20. The company has a debt-to-equity ratio of 0.40, a quick ratio of 2.65 and a current ratio of 3.39.

Hedge Funds Weigh In On Pharming Group

An institutional investor recently raised its position in Pharming Group stock. Silverberg Bernstein Capital Management LLC raised its position in shares of Pharming Group (NASDAQ:PHAR) by 75.4% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 41,110 shares of the company’s stock after purchasing an additional 17,675 shares during the quarter. Silverberg Bernstein Capital Management LLC owned 0.06% of Pharming Group worth $339,000 as of its most recent SEC filing. 0.03% of the stock is currently owned by institutional investors.

About Pharming Group

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.